Co-Dx reports Q2 2026 net loss of $6.3 million
Revenue was $0.17M and the company filed a 510(k) for its respiratory test and expanded in Saudi Arabia.
See the latest news and media coverage for Co-Dx. We track all announcements, press releases, and industry mentions in real time, all in one place.
Real-time PCR diagnostic test developer
co-dx.comLast updated
In short: Co-Dx submitted its first FDA 510(k) for an upper respiratory test and advanced global expansions through joint ventures in India and KSA.
Revenue was $0.17M and the company filed a 510(k) for its respiratory test and expanded in Saudi Arabia.
The submission includes a concurrent CLIA Waiver by Application for use on the Co-Dx PCR Pro instrument in decentralized settings, following clinical studies with over 1,400 patients.
PCR Pro instruments and MTB test kits deployed to select labs for evaluation, delivering rapid PCR results in 30 minutes.
He brings over 20 years of molecular diagnostics experience and will lead R&D for FDA submissions.
Moby summary of Co-Diagnostics, Inc.'s Q2 2026 earnings call...
The molecular diagnostics company's concurrent CLIA Waiver by Application, if granted, would allow testing in decentralised point-of-care settings.
Detailed price information for Co-Diagnostics Inc (CODX-Q) from The Globe and Mail including charting and trades.
Co-Diagnostics Inc. (NASDAQ:CODX) on Wednesday said CoSara Diagnostics Pvt. Ltd, its joint venture...
Track Co-Dx and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Co-Dx and other trending companies.